Clinical trials
Completed Phase 3 Renal Insufficiency, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
203 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 9 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 16 |
| 2008 | 6 |
| 2009 | 13 |
| 2010 | 10 |
| 2011 | 10 |
| 2012 | 15 |
| 2013 | 15 |
| 2014 | 10 |
| 2015 | 17 |
| 2016 | 13 |
| 2017 | 12 |
| 2018 | 12 |
| 2019 | 6 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 203 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 22 |
| Tanabe Pharma Corporation | 8 |
| Astellas Pharma Inc | 7 |
| Bayer | 7 |
| GlaxoSmithKline | 7 |
| Akebia Therapeutics | 6 |
| Genzyme, a Sanofi Company | 6 |
| Abbott | 5 |
| Kyntra Bio | 5 |
| Pharmacosmos A/S | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency, Chronic | 203 |
| Anemia | 55 |
| Kidney Failure, Chronic | 35 |
| Kidney Diseases | 25 |
| Renal Insufficiency | 22 |
| Hyperphosphatemia | 20 |
| Hyperparathyroidism, Secondary | 13 |
| Diabetes Mellitus, Type 2 | 10 |
| Anemia, Iron-Deficiency | 8 |
| Hyperparathyroidism | 5 |
Trials
Showing 1 to 25 of 203. Each trial links to its page on Pharma Observatory.
103 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.